PE20120348A1 - Combinacion que comprende cabazitaxel y capecitabina - Google Patents

Combinacion que comprende cabazitaxel y capecitabina

Info

Publication number
PE20120348A1
PE20120348A1 PE2011001906A PE2011001906A PE20120348A1 PE 20120348 A1 PE20120348 A1 PE 20120348A1 PE 2011001906 A PE2011001906 A PE 2011001906A PE 2011001906 A PE2011001906 A PE 2011001906A PE 20120348 A1 PE20120348 A1 PE 20120348A1
Authority
PE
Peru
Prior art keywords
capecitabin
cabazitaxel
combination including
solvate
including cabazitaxel
Prior art date
Application number
PE2011001906A
Other languages
English (en)
Inventor
Emmanuelle Magherini
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20120348A1 publication Critical patent/PE20120348A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE CABAZITAXEL Y CAPECITABINA, LOS CUALES PUEDEN ESTAR EN SU FORMA BASE, SAL DE ACIDO, HIDRATO O SOLVATO. DE PREFERENCIA, EL CABAZITAXEL SE ENCUENTRA BAJO LA FORMA DE SOLVATO ACETONICO Y CONTIENE ENTRE 5% Y 8% EN PESO DE ACETONA. DICHA COMBINACION TIENE ACTIVIDAD ANTITUMORAL Y ES UTIL EN PACIENTES CON CANCER DE MAMA METASTASICO
PE2011001906A 2009-05-06 2010-05-06 Combinacion que comprende cabazitaxel y capecitabina PE20120348A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902189A FR2945211A1 (fr) 2009-05-06 2009-05-06 Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
FR0902264A FR2945212B1 (fr) 2009-05-06 2009-05-11 Combinaison antitumorale comprenant le cabazitaxel et la capecitabine

Publications (1)

Publication Number Publication Date
PE20120348A1 true PE20120348A1 (es) 2012-04-24

Family

ID=41168737

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001906A PE20120348A1 (es) 2009-05-06 2010-05-06 Combinacion que comprende cabazitaxel y capecitabina

Country Status (25)

Country Link
US (1) US20120115806A1 (es)
EP (1) EP2427187A1 (es)
JP (1) JP2012526089A (es)
KR (1) KR20120008069A (es)
CN (1) CN102458392A (es)
AU (1) AU2010244253A1 (es)
BR (1) BRPI1011827A2 (es)
CA (1) CA2761079A1 (es)
CL (1) CL2011002774A1 (es)
CO (1) CO6390103A2 (es)
CR (1) CR20110586A (es)
DO (1) DOP2011000336A (es)
EA (1) EA201171360A1 (es)
EC (1) ECSP11011435A (es)
FR (2) FR2945211A1 (es)
IL (1) IL216063A0 (es)
MA (1) MA33343B1 (es)
MX (1) MX2011011765A (es)
NI (1) NI201100192A (es)
NZ (1) NZ596226A (es)
PE (1) PE20120348A1 (es)
SG (1) SG175894A1 (es)
TN (1) TN2011000542A1 (es)
WO (1) WO2010128258A1 (es)
ZA (1) ZA201108109B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024186B1 (ru) 2009-10-29 2016-08-31 Авентис Фарма С.А. Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты
CN102068407B (zh) * 2010-12-27 2011-11-23 江苏奥赛康药业股份有限公司 一种cabazitaxel注射液及其制备方法
EP2620148A1 (en) 2012-01-27 2013-07-31 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
HUE046232T2 (hu) 2011-02-25 2020-02-28 Sanofi Mature Ip Kabazitaxelt és ciszplatint tartalmazó tumorellenes kombináció
EP2491925A1 (en) 2011-02-25 2012-08-29 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
BR212016030926U2 (pt) * 2014-06-30 2018-05-29 Tarveda Therapeutics Inc conjugados de alvo e partículas e formulações dos mesmos
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Also Published As

Publication number Publication date
CL2011002774A1 (es) 2012-04-20
FR2945212A1 (fr) 2010-11-12
JP2012526089A (ja) 2012-10-25
MA33343B1 (fr) 2012-06-01
US20120115806A1 (en) 2012-05-10
NI201100192A (es) 2012-01-23
CR20110586A (es) 2011-12-13
TN2011000542A1 (fr) 2013-05-24
DOP2011000336A (es) 2011-12-15
CO6390103A2 (es) 2012-02-29
CA2761079A1 (fr) 2010-11-11
IL216063A0 (en) 2012-01-31
EP2427187A1 (fr) 2012-03-14
MX2011011765A (es) 2012-06-01
KR20120008069A (ko) 2012-01-25
EA201171360A1 (ru) 2012-05-30
WO2010128258A1 (fr) 2010-11-11
FR2945211A1 (fr) 2010-11-12
NZ596226A (en) 2014-01-31
FR2945212B1 (fr) 2011-07-01
AU2010244253A1 (en) 2011-11-24
ZA201108109B (en) 2013-01-30
BRPI1011827A2 (pt) 2016-03-22
ECSP11011435A (es) 2011-12-30
SG175894A1 (en) 2011-12-29
CN102458392A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
PE20120348A1 (es) Combinacion que comprende cabazitaxel y capecitabina
AR124607A2 (es) Arilquinazolinas
CR20120332A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos.
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
CL2016000873A1 (es) Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento.
CR20150370A (es) Compuestos antivirales
PE20121429A1 (es) Nuevo uso antitumoral de cabazitaxel
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
UY33735A (es) Compuestos antivirales
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CR20120113A (es) (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer
BR112014027601A2 (pt) picolinamidas macrocíclicas como fungicidas
AR100006A1 (es) Derivados de tubulisina
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
UY32404A (es) 4-aril-butan-1,3-diamidas
MX2019010875A (es) Derivados de uncialamicina, metodos de sintesis y su uso como agentes antitumor.
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
UY33509A (es) Metodos y composiciones para el tratamiento de la alergia
DOP2016000064A (es) Derivados de fenilalanina sustituidos
PH12018501351A1 (en) Cortistatin analogs and uses thereof
CU20150006A7 (es) Derivados de (piperidin-4-il)piperazina-1-carboxamida/carboxilato útiles como antagonistas del receptor -h3
UA111434C2 (uk) Фармацевтична композиція, що містить фімасартан і гідрохлортіазид
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
BR112014003096A2 (pt) uso de ccne2 como marcador de estratificação no tratamento de tumores de mama com inibidores de pan-cdk

Legal Events

Date Code Title Description
FC Refusal